• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assays
      • Transcreener® ADP² Kinase Assay
      • Transcreener® ADO CD73 Assay
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay
      • Transcreener® cGAMP cGAS Assay
      • Transcreener® EPIGEN SAH Methyltransferase Assay
      • Transcreener® GDP GTPase Assay Kits
      • Transcreener® UDP² Glycosyltransferase Assay
      • Transcreener® 2-5A OAS Assay
    • AptaFluor® HTS Assays
      • AptaFluor® SAH Methyltransferase Assay
    • HTS Assays by Target Family
      • Kinase Assay Kits
      • ATPase Assay Kits
      • Glycosyltransferase Assay Kits
      • GTPase Assay Kits
        • GAP Assay Kits
        • GEF Assay Kits
      • Ligase and Synthetase Assay Kits
      • Methyltransferase Assay Kits
      • Phosphodiesterase Assay Kits
    • HTS Assays by Target
      • Adenosine Kinase Assay Kits
      • AMPK Assay Kits
      • CD39 Assay Kits
      • CD73 Assay Kits
      • cGAS Assay Kits
      • DDX3 Assay Kits
      • ENPP1 Assay Kits
      • EZH2 Assay Kits
      • IKK-beta Assay Kits
      • IRAK4 Assay Kits
      • JAK1 Assay Kits
      • JAK3 Assay Kits
      • NSP13 Assay Kits
      • NUDT5 Assay Kits
      • OAS Assay Kits
      • TBK1 Assay Kits
    • Recombinant Enzymes
      • Human cGAS Enzyme
      • Mouse cGAS Enzyme
      • Human DDX3 Enzyme
      • Human OAS1 Enzyme
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • CD38 Assay Services
    • GTPase Profiling Services
  • Innate Immunity
    • Adenosine Kinase Activity Assays
    • AMPK Activity Assays
    • cGAS Activity Assays
    • CD73 Activity Assays
    • CD38 Activity Assay Services
    • CD39 Activity Assays
    • DDX3 Activity Assays
    • ENPP1 Activity Assays
    • IKK-beta Activity Assays
    • IRAK4 Activity Assays
    • JAK1 Activity Assays
    • JAK3 Activity Assays
    • NSP13 Activity Assays
    • OAS1 Activity Assays
    • TBK1 Activity Assays
  • Resources
    • Technical Manuals
    • Transcreener® Assays – Instrument Compatibility
    • Application Notes
    • Posters and Presentations
    • Publications
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
      • Kinases in Innate Immunity
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

Tag: Transcreener cGAMP cGAS Assay

NIH Awards BellBrook Labs Phase II Grant to Develop Drugs Targeting the cGAS-STING Pathway for Lupus and Related Autoimmune Diseases

Tuesday, 20 April 2021 by Bellbrook Labs
cGAS Phase II Press Release Graphic
The National Institute of Allergy and Infectious Diseases (NIAID) recently awarded BellBrook Labs a $1.8 million Phase II Small Business Innovative Research (SBIR) grant to develop small molecule antagonists of cyclic GAMP synthase (cGAS). The grant will enable BellBrook to optimize their cGAS lead molecules and test their efficacy for treating lupus-related UV light sensitivity
cGAS InhibitorsTranscreener cGAMP cGAS Assay
Read more
  • Published in Company, News
No Comments

New TR-FRET Readout Now Available with the Transcreener cGAMP cGAS Assay

Thursday, 10 December 2020 by Bellbrook Labs
New cGAS TR-FRET Assay
Launched in November 2019, the Transcreener cGAMP cGAS Assay has generated a great deal of interest in the drug discovery community. While fluorescence polarization (FP) readouts offer a stable and robust option, some researchers prefer time-resolved Förster-resonance-energy-transfer (TR-FRET) readouts for large screens. After months of development, BellBrook Labs is pleased to announce the addition of
cgas assaycGAS InhibitorsTranscreener cGAMP cGAS Assay
Read more
  • Published in News, Products
No Comments

Previously Recorded Webinar – Streamline cGAS Inhibitor Discovery with the Transcreener® cGAS Assay

Wednesday, 28 October 2020 by Bellbrook Labs
Webinar Graphic
The immune system uses the recognition of foreign nucleic acids and subsequent type I interferon production as a first line of defense in response to microbial invaders. Recent research has validated one key to this cascade, a unique cyclic dinucleotide – cGAMP. The enzyme cGAS produces this recently discovered molecular messenger. As an apoenzyme, cGAS
cgas assayTranscreener cGAMP cGAS Assay
Read more
  • Published in News
No Comments

BellBrook Labs Launches Transcreener cGAS Activity Assay to Accelerate Drug Discovery

Monday, 18 November 2019 by Bellbrook Labs
New Transcreener cGAS Assay
The new Transcreener cGAMP cGAS Assay directly measures the product cGAMP, in a cGAS enzymatic reaction allowing researchers to screen vast compound libraries for novel modulators. The assay will be used to discover and develop new treatments for autoimmune diseases and cancer by targeting the cGAS-STING pathway. Madison, WI – Researchers at BellBrook Labs have
Transcreener cGAMP cGAS Assay
Read more
  • Published in HTS Assays, News, Products
No Comments

BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases

Thursday, 11 July 2019 by Bellbrook Labs
cGAS Inhibitors Grant
The National Institute Of Allergy And Infectious Disease recently awarded BellBrook Labs a $300,000 Small Business Innovative Research (SBIR) grant to develop novel inhibitors for the cyclic GAMP Synthase (cGAS). The grant will be used to accelerate the discovery of new treatments for autoimmune diseases by targeting the cGAS-STING pathway. Madison, WI – July 2019
cGAS InhibitorsTranscreener cGAMP cGAS Assay
Read more
  • Published in News
No Comments

NIH Awards BellBrook Labs Phase II Grant to Develop HTS Assays Targeting the cGAS-STING Pathway for Autoimmune Diseases and Cancer

Tuesday, 22 May 2018 by Bellbrook Labs
Autoimmune Disease News
The National Institutes of General Medical Sciences (NIGMS) recently awarded BellBrook Labs a $1 million phase II Small Business Innovative Research (SBIR) grant to develop new assays to detect cyclic GMP-AMP (cGAMP) levels in biological samples. The assays will be used to discover, develop, and monitor new treatments for autoimmune diseases and cancer by targeting
Transcreener cGAMP cGAS Assay
Read more
  • Published in Company, Emerging Targets, News
No Comments

New Posters from DOT 2017

Friday, 29 September 2017 by Bellbrook Labs
Poster Presentations A Homogenous, High Throughput Assay to Measure Guanine Nucleotide Exchange Factor Activity Using Transcreener® GDP Assay Guanine nucleotide exchange factors (GEFs) positively regulate Rho GTPases by accelerating GDP dissociation to allow formation of the active, GTP-bound complex. Development of inhibitors that specifically disrupt GEF action on a target Rho GTPase may be a
AptaFluor SAH Methyltransferase AssayAssay Development Servicesdrug discovery servicesLead Discovery ServicesTranscreener AMP/GMP AssayTranscreener cGAMP cGAS AssayTranscreener GDP Assay
Read more
  • Published in HTS Assays, News
No Comments

BellBrook Labs Awarded NIH Grant to Develop a High Throughput cGAS Assay for Cancer and Autoimmune Disease Drug Discovery

Wednesday, 14 June 2017 by Bellbrook Labs
BellBrook Labs was recently awarded a $288,000 SBIR Phase I grant from the National Institutes of General Medical Sciences (NIGMS) to develop an HTS assay for cyclic GAMP synthase, an enzyme that triggers immune responses to viruses and tumors. The new assay will be used in an effort to screen for cGAS enzyme modulators as
Assay Development Servicesdrug discovery servicesLead Discovery ServicesTranscreener cGAMP cGAS Assay
Read more
  • Published in Emerging Targets, HTS Assays, News
No Comments

Fighting Infection’s Ghost

Wednesday, 15 June 2016 by Robyn Perrin
Aicardi–Goutières syndrome (AGS) is a rare and brutal genetic condition. Most infants born with the syndrome are asymptomatic at birth, but about 1 in 5 have enlarged spleen and liver, elevated liver enzymes in the blood, decreased platelet level, and abnormal neurological responses. Over the first year of life, things get much worse: episodes of
Transcreener cGAMP cGAS Assay
Read more
  • Published in Emerging Targets
No Comments

Viruses take the STING out of innate immunity

Thursday, 09 June 2016 by Robyn Perrin
Viral trespassers leave traces of themselves as they overtake cells. The presence of hallmark viral molecules—called PAMPs, for pathogen-associated molecular patterns—allows innate immune system sensors to detect the trail of viral substances as effectively as Sherlock Holmes in miniature. Some of these sensors, or pattern recognition receptors (PRRs), nose out viral DNA and RNA. When
Transcreener cGAMP cGAS Assay
Read more
  • Published in Emerging Targets
No Comments

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Innate Immunity
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • Scientist Studying ALKPK1

    The Role ALPK1 in Health and Disease

    ALPK1 (Alpha Kinase 1) is an atypical serine/th...
  • DHX36 RNA Helicase Unwinds G4 RNA Structures

    Resolving the Many Roles of DHX36

    While most researchers are familiar with canoni...
  • Researcher Studying MAPK14

    MAPK14 in Context

    MAPK14 (or p38 alpha or SAPK2a) is a proline-di...
  • PRMT5 Role with Macrophages

    PRMT5 is Innately Interesting

    PRMT5 is a type II arginine methyltransferase t...
  • IRE1 Proteins in ER

    The Multifaceted Roles of IRE1 Are Unfolding

    IRE1 (Inositol-Requiring Enzyme 1) is one of th...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2021 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP